# Illumina

> Illumina builds the sequencing instruments, consumables, assays, and software that turn DNA, RNA, and proteins into usable biological data. Its customers range from university labs and hospitals to pharmaceutical companies and public-health agencies. The company sells expensive laboratory platforms, but its economic engine is the proprietary chemistry used on every run: consumables supplied 74% of 2025 revenue. Now Illumina is extending that installed base into clinical oncology, proteomics, spatial biology, cloud analysis, and AI-ready datasets.

- **Founded:** 1998
- **Headquarters:** San Diego, United States
- **Founders:** David R. Walt (Co-founder and scientific founder), Larry Bock (Co-founder and early director), John Stuelpnagel (Co-founder and acting CEO), Anthony W. Czarnik (Co-founder and chief scientific officer), Mark Chee (Co-founder and scientist)
- **Team size:** Approximately 8,600 full-time employees, 50 part-time employees and 1,430 contingent workers as of December 28, 2025.
- **Products:** NovaSeq X Series, MiSeq i100 Series, NextSeq 1000 and 2000, Sequencing consumables and library preparation, Infinium microarrays
- **Notable:** Helped reduce the cost and increase the throughput of short-read next-generation sequencing across research and clinical markets., Built a portfolio of more than 9,000 patents, according to the company., Illumina technology supported more than 300,000 peer-reviewed studies in 2022, according to the company.

## Products & services

- **NovaSeq X Series** — High-throughput short-read sequencing systems for large-scale whole-genome, exome, transcriptome, oncology and multiomic projects.
- **MiSeq i100 Series** — Customer-installable benchtop sequencers with XLEAP-SBS chemistry and onboard or cloud DRAGEN analysis for smaller and faster workflows.
- **NextSeq 1000 and 2000** — Mid-throughput sequencing platforms used for applications including RNA sequencing, exomes and single-cell studies.
- **Sequencing consumables and library preparation** — Flow cells, reagents, cartridges, indexes, panels and kits required to prepare and run DNA and RNA samples.
- **Infinium microarrays** — BeadChip-based genotyping and methylation arrays for population studies, screening and applied markets.
- **DRAGEN** — Hardware-accelerated secondary-analysis pipelines for alignment, variant calling, compression and specialized genomic workflows.
- **Illumina Connected Software** — Cloud and on-premises tools including BaseSpace Sequence Hub, Connected Analytics, Connected Insights, Emedgene, Clarity LIMS and Connected Multiomics.
- **TruSight Oncology** — Research and diagnostic assay families for comprehensive genomic profiling and oncology biomarker analysis.
- **Illumina Protein Prep** — NGS-read proteomics workflow based on SOMAmer affinity reagents, strengthened by the 2026 SomaLogic acquisition.
- **StrataMap Spatial** — End-to-end spatial whole-transcriptome research solution with single-cell resolution and sequencing-based readout.
- **TruPath Genome** — Mapped-read whole-genome workflow intended to improve visibility into structural variants and difficult genomic regions on short-read platforms.

## Achievements

- Helped reduce the cost and increase the throughput of short-read next-generation sequencing across research and clinical markets.
- Built a portfolio of more than 9,000 patents, according to the company.
- Illumina technology supported more than 300,000 peer-reviewed studies in 2022, according to the company.
- Exceeded one billion lives covered for noninvasive prenatal testing, according to the company.
- Generated $4.34 billion of fiscal 2025 revenue with a 66.1% consolidated gross margin.
- Completed the spin-off of GRAIL in 2024, returning focus to the core sequencing business.
- Completed the acquisition of SomaLogic in January 2026, expanding its proteomics capabilities.

## Latest updates

- **2026-07** — Reported Q2 revenue of $1.16 billion, up 9.5% year over year, and raised full-year revenue guidance to $4.60-$4.64 billion.
- **2026-07** — Expanded the Billion Cell Atlas alliance with three AI drug developers, including Formation Bio.
- **2026-06** — Launched StrataMap Spatial for sequencing-based whole-transcriptome mapping at single-cell resolution.
- **2026-05** — Introduced fireflyGO with SPT Labtech and a distributed whole-genome MRD research solution.
- **2026-03** — Expanded its Labcorp precision-oncology collaboration and announced a preventive-genomics consortium with Veritas Genetics.
- **2026-02** — Launched TruPath Genome and outlined planned NovaSeq X advances in output, speed, flexibility and data quality.
- **2026-01** — Completed the SomaLogic acquisition and launched Connected Multiomics and the Billion Cell Atlas.

## Links

- Website: https://www.illumina.com
- LinkedIn: https://www.linkedin.com/company/illumina
- Twitter/X: https://x.com/illumina
- GitHub: https://github.com/Illumina
- YouTube: https://www.youtube.com/user/IlluminaInc
- Instagram: https://www.instagram.com/illuminainc
- Facebook: https://www.facebook.com/illuminainc
- TikTok: https://www.tiktok.com/@illuminainc

---

Profile page: https://yespress.io/illumina
Published by YesPress — https://yespress.io
Last updated: 2026-08-14